Search filters

List of works by Andreas Wollenberg

2020 European guideline on the management of genital molluscum contagiosum

scientific article published on 02 September 2020

A systematic review of factors influencing treatment adherence in chronic inflammatory skin disease - strategies for optimizing treatment outcome

scientific article published on 14 November 2019

Baseline characteristics, disease severity and treatment history of patients with atopic dermatitis included in the German AD Registry TREATgermany

scientific article published on 13 November 2019

Dupilumab provides rapid and sustained improvement in SCORAD outcomes in adults with moderate-to-severe atopic dermatitis: combined results of four randomized phase 3 trials

scientific article published on 29 April 2020

ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children

scientific article published on 17 November 2020

Efficacy of a skin care cream with TRPV1 inhibitor 4-t-butylcyclohexanol in the topical therapy of perioral dermatitis

scientific article published on 29 October 2019

European Task Force on Atopic Dermatitis (ETFAD) statement on severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2)-infection and atopic dermatitis

scientific article published on 29 March 2020

Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS)

scientific article published on 13 August 2019

Pathomechanism of dupilumab-associated inflammatory eye symptoms

scientific article published on 03 July 2019

Quality of care in atopic dermatitis - a position statement by the European Task Force on Atopic Dermatitis (ETFAD)

scientific article published on 05 December 2019

The role of bacterial skin infections in atopic dermatitis: expert statement and review from the International Eczema Council Skin Infection Group

scientific article published on 01 November 2019

Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)

scientific article published on 30 September 2020

Paulina is supported by:

About Paulina

Help